EMA recommends Gilead Sciences' Lenacapavir for HIV prevention, with FDA approval and generic options available soon.

An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

Long-acting lenacapavir has been shown to be a promising option for HIV PrEP and is now recommended globally by WHO, with a ...

The EU has approved an injectable HIV drug offering a two-month dosage schedule, marking a breakthrough in treatment ...

It was supposed to be a banner year in the fight against the HIV epidemic. Nationwide infection rates were gradually falling, ...

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which ...

LONDON -- The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, ...

DAP Health has received the new twice-yearly injection for HIV prevention. Here's what you need to know if you're interested ...

Pre-exposure prophylaxis (PrEP), as an effective means to reduce new HIV infections in high-risk populations, is listed as ...

The drug is administered subcutaneously twice a year, making it easier for high-risk patients to comply with prophylaxis.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...